Early identification of patients at risk of death due to infections, hemorrhage, or graft failure after allogeneic bone marrow transplantation on the basis of the leukocyte counts

Bone Marrow Transplantation

Volumn 19, Issue 4, 1997, Pages 349-355

  Mehta, J ^a   Powles, R ^a   Singhal, S ^a   Horton, C ^a   Middleton, G ^a   Eisen, T ^a   Meller, S ^a   Pinkerton, C R ^a   Treleaven, J ^a  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

Author keywords

Graft failure; Growth factors; Hemorrhage; Infections; Leukocyte count; Leukopenia

Indexed keywords

GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; GROWTH FACTOR;

ADOLESCENT; ADULT; ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; CHILD; CLINICAL TRIAL; DEATH; DRUG USE; FEMALE; GRAFT FAILURE; HIGH RISK PATIENT; HLA MATCHING; HUMAN; INFECTION; LEUKOCYTE COUNT; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PREDICTION; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION;

EID: 0031051789     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1700657     Document Type: Article

References (31)

1. Storb R, Prentice RL, Thomas ED et al. Factors associated with graft rejection after HLA-identical marrow transplantation for aplastic anaemia. Br J Haematol 1983; 55: 573-585.
2. Powles RL, Morgenstern GR, Kay HE et al. Mismatched family donors for bone-marrow transplantation as treatment for acute leukaemia. Lancet 1983; 1: 612-615.
3. Niederwieser D, Pepe M, Storb R et al. Improvement in rejection, engraftment rate and survival without increase in graft-versus-host disease by high marrow cell dose in patients transplanted for aplastic anaemia. Br J Haematol 1988; 69: 23-28.
4. Martin PJ, Hansen JA, Torok-Storb B et al. Graft failure in patients receiving T cell-depleted HLA-identical allogeneic marrow transplants. Bone Marrow Transplant 1988; 3: 445-456.
5. Anasetti C, Amos D, Beatty PG et al. Effect of HLA compatibility on engraftment of bone marrow transplants in patients with leukemia or lymphoma. New Engl J Med 1989; 320: 197-204.
6. Nemunaitis J, Singer JW, Buckner CD et al. Use of recombinant human granluocyte-macrophage colony-stimulating factor in graft failure after bone marrow transplantation. Blood 1990; 76: 245-253.
7. Quinones RR. Hematopoietic engraftment and graft failure after bone marrow transplantation. Am J Pediatr Hematol Oncol 1993; 15: 3-17.
8. Mehta J, Powles RL, Mitchell P et al. Graft failure after bone marrow transplantation from unrelated donors using busulphan and cyclophosphamide for conditioning. Bone Marrow Transplant 1994; 13: 583-587.
9. Schultz KR, Ratanatharathorn V, Abella E et al. Graft failure in children receiving HLA-mismatched marrow transplants with husulfan-containing regimens. Bone Marrow Transplant 1994; 13: 817-822.
10. Davies SM, Ramsay NK, Haake RJ et al. Comparison of engraftment in recipients of matched sibling or unrelated donor marrow allografts. Bone Marrow Transplant 1994; 13: 51-57.
11. Weisdorf DJ. Verfaillie CM. Davies SM et al. Hematopoietic growth factors for graft failure after bone marrow transplantation: a randomized trial of granulocyte-macrophage colony-stimulating factor (GM-CSF) versus sequential GM-CSF plus granulocyte-CSF. Blood 1995; 85: 3452-3456.
12. Bolger GB, Sullivan KM, Storb R et al. Second marrow infusion for poor graft function after allogeneic marrow transplantation. Bone Marrow Transplant 1986; 1: 21-30.
13. Bunjes D, Wiesneth M, Hertenstein B et al. Graft failure after T cell-depleted bone marrow transplantation: clinical and immunological characteristics and response to immunosuppressive therapy. Bone Marrow Transplant 1990; 6: 309-314.
14. Klingemann HG, Eaves AC, Barnett MJ et al. Recombinant GM-CSF in patients with poor graft function after bone marrow transplantation. Clin Invest Med 1990; 13: 77-81.
15. Davies SM, Weisdorf DJ, Haake RJ et al. Second infusion of bone marrow for treatment of graft failure after allogeneic bone marrow transplantation. Bone Marrow Transplant 1994; 14: 73-77.
16. Mehta J, Powles R, Singhal S et al. Outcome of autologous rescue after failed engraftment of allogeneic marrow. Bone Marrow Transplant 1996; 17: 213-217.
17. Peralvo J, Bacigalupo A, Pittaluga PA et al. Poor graft function associated with graft-versus-host disease after allogeneic marrow transplantation. Bone Marrow Transplant 1987; 2: 279-285.
18. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-481.
19. Peto R, Pike MC, Armitage P et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. Analysis and examples. Br J Cancer 1977; 35: 1-39.
20. Cox DR. Regression models and life-tables. J R Stat Soc [B] 1972; 34: 187-220.
21. Mehta J, Powles R, Horton C et al. The relationship between donor-recipient blood group incompatibility and serum bilirubin after allogeneic bone marrow transplantation from HLA-identical siblings. Bone Marrow Transplant 1995; 15: 853-858.
22. Hale G, Waldmann H. Control of graft-versus-host disease and graft rejection by T cell depletion of donor and recipient with Campath-1 antibodies. Results of matched sibling transplants for malignant diseases. Bone Marrow Transplant 1994; 13: 597-611.
23. Powles R, Smith C, Milan S et al. Human recombinant GM-CSF in allogeneic bone-marrow transplantation for leukaemia: double-blind, placebo-controlled trial. Lancet 1990; 336: 1417-1420.
24. Slavin S, Naparstek E, Aker M et al. The use of total lymphoid irradiation (TLI) for prevention of rejection of T-lymphocyte depleted bone marrow allografts in non-malignant hematological disorders. Transplant Proc 1989; 21: 3053-3054.
25. Or R, Mehta J, Kapelushnik J et al. Total lymphoid irradiation, anti-lymphocyte globulin and Campath 1-G for immunosuppression prior to bone marrow transplantation for aplastic anemia after repeated graft rejection. Bone Marrow Transplant 1994; 13: 97-99.
26. Weber RJ. Pharmacoeconomic issues in the use of granulocyte-macrophage colony-stimulating factor for bone marrow transplantation or chemotherapy-induced neutropenia. Clin Ther 1993; 15: 180-191.
27. Atkinson K, Biggs JC, Downs K et al. GM-CSF after allogeneic bone marrow transplantation: accelerated recovery of neutrophils, monocytes and lymphocytes. Aust NZ J Med 1991; 21: 686-692.
28. Nemunaitis J, Anasetti C, Storb R et al. Phase II trial of recombinant human granulocyte-macrophage colony-stimulat-ing factor in patients undergoing allogeneic bone marrow transplantation from unrelated donors. Blood 1992; 79: 2572-2577.
29. Anasetti C, Anderson G, Appelbaum FR et al. Phase III study of rhGM-CSF in allogeneic marrow transplantation from unrelated donors. Blood 1993; 82 (Suppl. 1): 454a (Abstr.).
30. Schriber JR, Chao NJ, Long GD et al. Granulocyte colony-stimulating factor after allogeneic bone marrow transplantation. Blood 1994; 84: 1680-1684.
31. Körbling M, Przepiorka D, Huh YO et al. Allogeneic blood stem cell transplantation for refractory leukemia and lymphoma: potential advantage of blood over marrow allografts. Blood 1995; 85: 1659-1665.